News | 08 December 2022
Wockhardt promoters sell stake
The proceeds of the issue has been/will be reinvested in the company and to meet its own business requirements.
The proceeds of the issue has been/will be reinvested in the company and to meet its own business requirements.
Shandong Meditech Medical Technology is a manufacturer of onsite oxygen solutions for the healthcare market.
The use of procalcitonin testing for sepsis management is highest in the US
The IPO is a complete OFS by existing shareholder Helix Investment Holdings
Proceeds from the transaction will be reinvested towards the growth, innovation and expansion of Healthium’s advanced surgery, orthopaedics, wound care and post-surgical care portfolio
GMP-compliant documentation of all manufacturing steps for cell and gene therapies
TTK Healthcare Limited received from BSV Pharma Pvt. Ltd. a sum of Rs. 593.11 crore on 9th May, 2022
The initiative has garnered the distinction of being the world’s largest government owned telemedicine platform
Natco Chlorantraniliprole (CTPR) Process does not infringe FMC's Indian Patent 298645.
The two-day event focused on the multi-faceted relationship of clinical research stakeholders and looked at bridging the academic and clinical research gap.
Move to increase affordability and accessibility for heart failure patients across the country
It offers quick relief in various types of Coughs, Colds and Sore Throat,
Expanded capacity in Nansha, China will support mid-scale manufacturing to ensure a smooth transition between early-phase and large-scale commercial production
Evaluating Investigational Sitravatinib in combination with Nivolumab for patients with non-squamous non-small cell lung cancer
Antibody levels remained above baseline six months after completion of a three-dose (Month 0-2-6) or a two-dose (Month 0-6) vaccination schedule
Presentations include new data on investigational medicines – favezelimab (MK-4280), zilovertamab vedotin (MK-2140) and nemtabrutinib – as well as KEYTRUDA (pembrolizumab) in multiple blood cancers
Application includes data from key phase III trials, including the pivotal MOMENTUM trial, which met all primary and key secondary efficacy endpoints
Phase-III trials were conducted for safety, and immunogenicity in around 3,100 subjects, in 14 trial sites across India (supported by BIRAC)
With this QIP placement, the Dhanuka group, which took over the company in 2018, is also meeting its mandatory obligation to dilute 15 percent stake in the company by March 2023
Subscribe To Our Newsletter & Stay Updated
